The 2018 ESC/ESH hypertension guidelines: Should nephrologists always stop at the lower boundary?
- 30 August 2018
- journal article
- editorial
- Published by Oxford University Press (OUP) in Journal Of Nephrology
- Vol. 31 (5) , 621-626
Abstract
In patients with chronic kidney disease (CKD), hypertension is a major challenge because of its high prevalence, the consequent increase in cardiovascular morbidity and mortality, and the risk it confers specifically to the progression of kidney disease. Hence, establishing evidence-based blood pressure targets and treatment strategies is a clinical priority of paramount importance. Over the last few years, different guidelines have advocated different blood pressure treatment thresholds and goals in CKD patients, including a target < 140/90 mmHg and a more intensive target—lower than 130/80 mmHg—in the presence of albuminuria ≥ 300 mg/daily. Aim of this article is to critically appraise the evidence base of the freshly released 2018 ESC/ESH European Guidelines, which recommend to lower systolic BP to a range 130 to < 140 mmHg in patients with diabetic or non-diabetic CKD, also in view of the 2017 US guidelines, which favor a more intensive strategy with a BP target lower than 130/80 mmHg.Keywords
This publication has 23 references indexed in Scilit:
- Blood pressure and low-density lipoprotein-cholesterol lowering for prevention of strokes and cognitive declineJournal Of Hypertension, 2014
- Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysisCanadian Medical Association Journal, 2013
- 2013 ESH/ESC Guidelines for the management of arterial hypertensionEuropean Heart Journal, 2013
- Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysisThe Lancet, 2012
- KDIGO clinical practice guidelines for bisphosphonate treatment in chronic kidney diseaseKidney International, 2011
- Effects of Intensive Blood-Pressure Control in Type 2 Diabetes MellitusNew England Journal of Medicine, 2010
- Blood Pressure Components and the Risk for End-Stage Renal Disease and Death in Chronic Kidney DiseaseClinical Journal of the American Society of Nephrology, 2009
- Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysisJournal of Clinical Epidemiology, 2008
- Impact of Achieved Blood Pressure on Cardiovascular Outcomes in the Irbesartan Diabetic Nephropathy TrialJournal of the American Society of Nephrology, 2005
- Progression of Chronic Kidney Disease: The Role of Blood Pressure Control, Proteinuria, and Angiotensin-Converting Enzyme Inhibition: A Patient-Level Meta-AnalysisAnnals of Internal Medicine, 2003